Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet; 17 of the 119 sources its claims cite were checked for support.

The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review

Open access
Sørensen, Anders, Ruhé, Henricus G., Munkholm, Klaus · 2022 · Molecular Psychiatry

Abstract

Brain imaging techniques enable the visualization of serotonin transporter (SERT) occupancy as a measure of the proportion of SERT blocked by an antidepressant at a given dose. We aimed to systematically review the evidence on the relationship between antidepressant dose and SERT occupancy. We searched PubMed and Embase (last search 20 May 2021) for human in vivo, within-subject PET, or SPECT studies measuring SERT occupancy at any dose of any antidepressant with highly selective radioligands ([ 11 C]-DASB, [ 123 I]-ADAM, and [ 11 C]-MADAM). We summarized and visualized the dose-occupancy relationship for antidepressants across studies, overlaying the plots with a curve based on predicted values of a standard 2-parameter Michaelis–Menten model fitted using the observed data. We included seventeen studies of 10 different SSRIs, SNRIs, and serotonin modulators comprising a total of 294 participants, involving 309 unique occupancy measures. Overall, following the Michaelis–Menten equation, SERT occupancy increased with a higher dose in a hyperbolic relationship, with occupancy increasing rapidly at lower doses and reaching a plateau at approximately 80% at the usual minimum recommended dose. All the studies were small, only a few investigated the same antidepressant, dose, and brain region, and few reported information on factors that may influence SERT occupancy. The hyperbolic dose-occupancy relationship may provide mechanistic insight of relevance to the limited clinical benefit of dose-escalation in antidepressant treatment and the potential emergence of withdrawal symptoms. The evidence is limited by non-transparent reporting, lack of standardized methods, small sample sizes, and short treatment duration. Future studies should standardize the imaging and reporting procedures, measure occupancy at lower antidepressant doses, and investigate the moderators of the dose-occupancy relationship.

Overview

CoChat Summary

TL;DR

This systematic review of within-subject PET/SPECT studies found that antidepressant dose and serotonin transporter (SERT) occupancy follow a hyperbolic relationship, with occupancy rising steeply at low doses and plateauing at approximately 80% at the usual minimum recommended dose. The authors suggest this may help explain the limited clinical benefit of dose escalation and the emergence of withdrawal symptoms during tapering.

Key findings

  • Across 17 studies, 10 antidepressants, 294 participants, and 309 unique occupancy measures, SERT occupancy increased hyperbolically with dose and reached an apparent plateau of approximately 80% at roughly the usual minimum recommended dose for depression.
  • Reported ED50 values in mg were 3.4 for citalopram, 9.1 for sertraline, 5 for paroxetine, 2.7 for fluoxetine, 5.8 for venlafaxine, 7.9 for duloxetine, 8.5 for vortioxetine, and 14.4 for desvenlafaxine.
  • Three studies measuring occupancy after single and repeated dosing found higher occupancy after repeated dosing: duloxetine 20 mg increased from 65% to 78% after 4 days; citalopram 20 mg and escitalopram 10 mg increased from 73% and 74% to 80% and 77% after 25 days; vortioxetine 2.5, 10, and 60 mg increased from 27%, 44%, and 70% to 35%, 63%, and 93% after 9 days.
  • For escitalopram, citalopram, and sertraline, but not paroxetine and fluvoxamine, SERT occupancy appeared to decrease more slowly than plasma concentration over time.

Methods

  • Systematic review registered at Open Science Framework and reported per PRISMA; searched PubMed and Embase (last search 20 May 2021) for human in vivo within-subject PET or SPECT studies measuring SERT occupancy at any dose of any approved oral antidepressant.
  • Included studies used highly selective radioligands [11C]-DASB, [123I]-ADAM, or [11C]-MADAM; 16 articles reporting 17 unique studies were included after screening 793 abstracts and 100 full texts.
  • Data were extracted independently by two researchers; because meta-analysis was not meaningful, occupancy was presented by dose, drug, and brain region as means and SDs, and dose-occupancy relationships were visualized with a fitted 2-parameter Michaelis–Menten model for antidepressants administered at four or more doses.

Limitations

  • The authors state that studies were small, few investigated the same antidepressant, dose, and brain region, and few reported factors influencing SERT occupancy; evidence is limited by non-transparent reporting, lack of standardized methods, small sample sizes, and short treatment duration.
  • The authors also note that different reference tissue models were combined, brain-region comparisons may not be clinically meaningful, the search may have missed studies due to inconsistent nomenclature, fitted curves did not consider individual study sample sizes, dose ranges were limited for some drugs, single- and repeated-dosing regimens could not be stratified, and co-medication effects could not be explored.
  • Evident from the text: most included studies investigated healthy individuals aged roughly 25–40 years, most were male, and some doses were investigated in only one to three participants, limiting generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41380-021-01285-w

Cites

Statistics

Nothing to recompute.

Figures

Fig. 1 Occupancy and dose relationship for antidepressants administered at four or more doses. The dose-occupancy relationship for antidepressants that were administered at four or more different doses (citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, paroxetine, venlafaxine, and vortioxetine), fitted according to a 2-parameter Michaelis–Menten model as f(x,K,Vm)=Vmx/(K+x), where Vm is the horizontal asymptote (expressing maximum occupancy), x is the drug dose and the parameter K is the dose where the occupancy is halfway between 0 and Vm. The parameter estimates Vm and K for each model are provided in Supplementary Table 2. For each individual figure, studies are represented by uniquely colored dots; the size of the dots is proportional to the number of occupancy measures. Dashed vertical lines represent the usual minimum recommended dose.
Fig. 1 Occupancy and dose relationship for antidepressants administered at four or more doses. The dose-occupancy relationship for antidepressants that were administered at four or more different doses (citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, paroxetine, venlafaxine, and vortioxetine), fitted according to a 2-parameter Michaelis–Menten model as f(x,K,Vm)=Vmx/(K+x), where Vm is the horizontal asymptote (expressing maximum occupancy), x is the drug dose and the parameter K is the dose where the occupancy is halfway between 0 and Vm. The parameter estimates Vm and K for each model are provided in Supplementary Table 2. For each individual figure, studies are represented by uniquely colored dots; the size of the dots is proportional to the number of occupancy measures. Dashed vertical lines represent the usual minimum recommended dose.CC BY · PubMed Central
Fig. 2 Time-course of occupancy and plasma/serum concentration. The relationship between serotonin transporter occupancy and plasma/serum concentration as it decreases over time after dose administration of escitalopram, citalopram, sertraline, paroxetine, and fluvoxamine. mg milligram, N number of participants, SERT Serotonin transporter, H hours after drug administration, Occ serotonin transporter occupancy, ng/mL nanograms per milliliter, nmol/L nanomoles per litre.
Fig. 2 Time-course of occupancy and plasma/serum concentration. The relationship between serotonin transporter occupancy and plasma/serum concentration as it decreases over time after dose administration of escitalopram, citalopram, sertraline, paroxetine, and fluvoxamine. mg milligram, N number of participants, SERT Serotonin transporter, H hours after drug administration, Occ serotonin transporter occupancy, ng/mL nanograms per milliliter, nmol/L nanomoles per litre.CC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 1 Not valid · 30 Not checked · 55 Own results and interpretations

35 more claims · 1 with their cited sources checked

Create a free account to see all 98 claims and to verify the 102 references still open.

See all claims — free account
  • Probably not a substantial claim. 30
  • It may state two separate claims as one. 37

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

The citation lists are queued

They are fetched later and appear here then.

References 62 · Cited by 65

Research works printed but not linked: 2

  1. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007;32:86–102.
  2. Areberg J, Mahableshwarkar A, Sanchez C. Vortioxetine: exploratory analysis of the relation between target engagement and integrated clinical database analysis of MADRS single items. Int J Neuropsychopharmacol 2014;17:58.

Metadata

Authors
Sørensen, A., Ruhé, H. G., & Munkholm, K.
Affiliations
  • Rigshospitalet (DK)
  • Radboud University Nijmegen (NL)
  • University of Southern Denmark (DK)
Corresponding author
Sørensen, Anders
Venue
Molecular Psychiatry
Published
2021-09-21
Volume
27
Issue
1
Pages
192-201
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3199137132
Cited by
65
References
62
Citations by year
2026: 12 · 2025: 16 · 2024: 13 · 2023: 13 · 2022: 11
FWCI
1.17
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
antidepressants, Michaelis-Menten model, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, PET radiotracer, [11C]DASB, antidepressant withdrawal symptoms
MeSH terms
Antidepressive Agents, Brain, Humans, Citalopram, Selective Serotonin Reuptake Inhibitors, Serotonin Plasma Membrane Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review. https://app.cochat.ai/papers/10.1038/s41380-021-01285-w
The paper
Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022). The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01285-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.